393 related articles for article (PubMed ID: 11371355)
1. T cell-specific loss of Pten leads to defects in central and peripheral tolerance.
Suzuki A; Yamaguchi MT; Ohteki T; Sasaki T; Kaisho T; Kimura Y; Yoshida R; Wakeham A; Higuchi T; Fukumoto M; Tsubata T; Ohashi PS; Koyasu S; Penninger JM; Nakano T; Mak TW
Immunity; 2001 May; 14(5):523-34. PubMed ID: 11371355
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation.
Suzuki A; Itami S; Ohishi M; Hamada K; Inoue T; Komazawa N; Senoo H; Sasaki T; Takeda J; Manabe M; Mak TW; Nakano T
Cancer Res; 2003 Feb; 63(3):674-81. PubMed ID: 12566313
[TBL] [Abstract][Full Text] [Related]
3. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination.
Suzuki A; Kaisho T; Ohishi M; Tsukio-Yamaguchi M; Tsubata T; Koni PA; Sasaki T; Mak TW; Nakano T
J Exp Med; 2003 Mar; 197(5):657-67. PubMed ID: 12615906
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor PTEN regulates T cell survival and antigen receptor signaling by acting as a phosphatidylinositol 3-phosphatase.
Wang X; Gjörloff-Wingren A; Saxena M; Pathan N; Reed JC; Mustelin T
J Immunol; 2000 Feb; 164(4):1934-9. PubMed ID: 10657643
[TBL] [Abstract][Full Text] [Related]
5. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium.
Dupont J; Renou JP; Shani M; Hennighausen L; LeRoith D
J Clin Invest; 2002 Sep; 110(6):815-25. PubMed ID: 12235113
[TBL] [Abstract][Full Text] [Related]
6. PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt.
Seminario MC; Precht P; Bunnell SC; Warren SE; Morris CM; Taub D; Wange RL
Eur J Immunol; 2004 Nov; 34(11):3165-75. PubMed ID: 15468057
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.
Stambolic V; Suzuki A; de la Pompa JL; Brothers GM; Mirtsos C; Sasaki T; Ruland J; Penninger JM; Siderovski DP; Mak TW
Cell; 1998 Oct; 95(1):29-39. PubMed ID: 9778245
[TBL] [Abstract][Full Text] [Related]
8. A surprising function for the PTEN tumor suppressor.
Hopkin K
Science; 1998 Nov; 282(5391):1027,1029-30. PubMed ID: 9841444
[No Abstract] [Full Text] [Related]
9. Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation.
Na SY; Patra A; Scheuring Y; Marx A; Tolaini M; Kioussis D; Hemmings BA; Hünig T; Bommhardt U
J Immunol; 2003 Aug; 171(3):1285-96. PubMed ID: 12874217
[TBL] [Abstract][Full Text] [Related]
10. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Suzuki A; de la Pompa JL; Stambolic V; Elia AJ; Sasaki T; del Barco Barrantes I; Ho A; Wakeham A; Itie A; Khoo W; Fukumoto M; Mak TW
Curr Biol; 1998 Oct; 8(21):1169-78. PubMed ID: 9799734
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo.
Jones RG; Parsons M; Bonnard M; Chan VS; Yeh WC; Woodgett JR; Ohashi PS
J Exp Med; 2000 May; 191(10):1721-34. PubMed ID: 10811865
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
Gu J; Tamura M; Yamada KM
J Cell Biol; 1998 Nov; 143(5):1375-83. PubMed ID: 9832564
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.
Horie Y; Suzuki A; Kataoka E; Sasaki T; Hamada K; Sasaki J; Mizuno K; Hasegawa G; Kishimoto H; Iizuka M; Naito M; Enomoto K; Watanabe S; Mak TW; Nakano T
J Clin Invest; 2004 Jun; 113(12):1774-83. PubMed ID: 15199412
[TBL] [Abstract][Full Text] [Related]
17. Compound heterozygosity for Pten and SHIP augments T-dependent humoral immune responses and cytokine production by CD(4+) T cells.
Moody JL; Jirik FR
Immunology; 2004 Jul; 112(3):404-12. PubMed ID: 15196208
[TBL] [Abstract][Full Text] [Related]
18. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells.
Strauss G; Knape I; Melzner I; Debatin KM
J Immunol; 2003 Aug; 171(3):1172-82. PubMed ID: 12874203
[TBL] [Abstract][Full Text] [Related]
19. Impaired Fas response and autoimmunity in Pten+/- mice.
Di Cristofano A; Kotsi P; Peng YF; Cordon-Cardo C; Elkon KB; Pandolfi PP
Science; 1999 Sep; 285(5436):2122-5. PubMed ID: 10497129
[TBL] [Abstract][Full Text] [Related]
20. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.
Locke FL; Zha YY; Zheng Y; Driessens G; Gajewski TF
J Immunol; 2013 Aug; 191(4):1677-85. PubMed ID: 23851688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
